Valuation Metrics: From Attractive to Fair
National Peroxide’s price-to-earnings (P/E) ratio currently stands at 28.83, a figure that signals a fair valuation relative to its historical range and peer group. This marks a notable change from previous assessments where the stock was considered attractively valued. The price-to-book value (P/BV) ratio is at 0.93, indicating the stock is trading just below its book value, which often suggests a reasonable entry point for value-conscious investors.
Other valuation multiples include an enterprise value to EBIT (EV/EBIT) of 26.50 and an enterprise value to EBITDA (EV/EBITDA) of 8.83. These ratios suggest that while the stock is not cheap, it is not excessively expensive either, especially when compared to some of its peers in the commodity chemicals industry.
Peer Comparison Highlights
When benchmarked against competitors, National Peroxide’s valuation appears balanced. For instance, J.G. Chemicals, another fair-valued stock, trades at a higher P/E of 32.16 and a significantly elevated EV/EBITDA of 23.65. Titan Biotech, classified as very expensive, commands a P/E of 55.17 and an EV/EBITDA of 42.80, underscoring the premium investors place on its growth prospects.
Conversely, some peers like Nitta Gelatin and DCW are considered expensive but trade at lower P/E ratios of 14.11 and 28.53 respectively, with EV/EBITDA multiples below 9. Indo Borax & Chemicals and Oriental Aromatics are on the higher end of the valuation spectrum, with P/E ratios of 28.44 and 239.56 respectively, the latter reflecting a niche market premium.
Interestingly, Gulshan Polyols and TGV Sraac are rated as attractive stocks, with P/E ratios of 28.96 and 8.39 respectively, and EV/EBITDA multiples well below National Peroxide’s, suggesting potential alternatives for value investors seeking lower entry multiples.
Rising fast and still accelerating! This Small Cap from FMCG sector is riding pure momentum right now. Jump in before the rally reaches its peak!
- - Accelerating price action
- - Pure momentum play
- - Pre-peak entry opportunity
Financial Performance and Returns Context
National Peroxide’s recent stock price has shown modest gains, with a day change of 1.34% and a current price of ₹582.95, slightly above the previous close of ₹575.25. The stock has traded within a 52-week range of ₹350.00 to ₹699.00, indicating significant volatility over the past year.
In terms of returns, the stock has outperformed the Sensex year-to-date with a 24.56% gain compared to the benchmark’s negative 8.29%. However, over the trailing one-year period, National Peroxide has declined by 8.15%, underperforming the Sensex’s 3.04% loss. This mixed performance highlights the stock’s sensitivity to sectoral and market dynamics.
Quality and Efficiency Metrics
Return on capital employed (ROCE) and return on equity (ROE) are critical indicators of operational efficiency and shareholder value creation. National Peroxide’s ROCE stands at 3.44%, while ROE is marginally lower at 3.21%. These figures are relatively modest and suggest room for improvement in capital utilisation and profitability compared to industry standards.
The company’s PEG ratio is an exceptionally low 0.05, which typically signals undervaluation relative to earnings growth. However, given the low returns and fair valuation grade, this metric should be interpreted cautiously, factoring in the company’s growth prospects and sector cyclicality.
Valuation Grade Upgrade and Market Implications
On 3 August 2026, National Peroxide’s valuation grade was upgraded from Sell to Hold, reflecting the shift from attractive to fair valuation. This change indicates a more balanced risk-reward profile, where the stock is no longer considered a bargain but still holds potential for steady performance.
Investors should note that the micro-cap status of National Peroxide entails higher volatility and liquidity considerations. The current valuation multiples suggest that the market has priced in moderate growth expectations, aligning with the company’s recent financial results and sector outlook.
Sector and Industry Context
The commodity chemicals sector remains sensitive to raw material price fluctuations, regulatory changes, and global demand cycles. National Peroxide’s valuation and performance must be viewed within this broader context, where cyclical pressures can impact earnings and multiples.
Compared to its peers, National Peroxide’s valuation appears reasonable, especially when contrasted with very expensive stocks like Titan Biotech and Oriental Aromatics. This relative fairness may appeal to investors seeking exposure to commodity chemicals without the premium valuations of growth-oriented peers.
National Peroxide Ltd or something better? Our SwitchER feature analyzes this micro-cap Commodity Chemicals stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Investor Takeaway
National Peroxide Ltd’s transition from an attractive to a fair valuation grade signals a maturing investment case. While the stock no longer offers a deep value proposition, its current multiples remain reasonable within the commodity chemicals sector. The company’s modest returns on capital and equity, combined with a low PEG ratio, suggest that investors should weigh growth prospects carefully against valuation.
Given the stock’s micro-cap classification and sector cyclicality, a Hold rating appears prudent, reflecting balanced risk and reward. Investors seeking higher momentum or lower valuation alternatives may consider peers such as Gulshan Polyols or TGV Sraac, which offer attractive multiples and growth potential.
Overall, National Peroxide’s fair valuation and recent upgrade in rating underscore the importance of continuous monitoring of financial metrics and market conditions to capitalise on opportunities in the commodity chemicals space.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
